Post by
Quentin30 on Nov 22, 2022 6:52pm
Advanced Pancreatic Cancer Trial - NU 18I01
Another poster recently mentioned more data from the other Pancreatic Cancer trial in combination with Keytruda.
Well, this is from ClinicalTrials.Gov.
Terminated (The total accrual goal of 34 patients was not met. Stage 1 of the study did not meet the interim analysis criteria to move onto Stage 2 of the Simon 2 stage design.)
So, I find it somewhat peculiar that ONCY still have this trial listed in their pipeline, when the trial was terminated and went no further. It failed to meet the criteria to move into Phase II. Safe and well tolerated, but nothing else.
Still think this company is worth 8 billion..?
Comment by
Quentin30 on Nov 22, 2022 7:54pm
When in doubt... just post something else... As for the Goblet-1 data... well the market thought a lot of that... we're back down to where we were prior to the presentation... and thus the impact was.. a big fat NIL. If you are so convinced ONCY will be bought out soon for megbucks, how bout you make me an offer of 3 bucks on all my ONCY stock. :-)
Comment by
Noteable on Nov 22, 2022 7:59pm
Yep ....the Goblet-1 pancreatic study delivered the goods. Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolytics plans to present pancreatic cancer data to regulators to determine the most expeditious path to approval
Comment by
Buckhenry on Nov 22, 2022 8:06pm
sounds like u have 3 choices Quentin... sell...hold...or seek therapy for your bitterness.
Comment by
Hcallahan44 on Nov 22, 2022 8:45pm
lol quentin....yea canada how about 3 a share for my 62 k....tell you what i will give you the few understand discount and give them all to you for 2.50.....
Comment by
Lesalpes29 on Nov 23, 2022 6:29am
Not going to buy all your shares for 3$, I’m not rich enough! But Quinntinnn why don’t you sell your shares on open market if you are so sure it’s going lower and lower and lower...?